TYVASO DPI IS NOW APPROVED

Skip to main content

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content

DPI=dry powder inhaler; ILD=interstitial lung disease; PH=pulmonary hypertension.